Caseware UK (AP4) 2022.0.179 2022.0.179 2023-03-312023-03-319false2022-04-01No description of principal activity8falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 01524904 2022-04-01 2023-03-31 01524904 2021-04-01 2022-03-31 01524904 2023-03-31 01524904 2022-03-31 01524904 c:CompanySecretary1 2022-04-01 2023-03-31 01524904 c:Director1 2022-04-01 2023-03-31 01524904 c:RegisteredOffice 2022-04-01 2023-03-31 01524904 d:Buildings 2022-04-01 2023-03-31 01524904 d:Buildings 2023-03-31 01524904 d:Buildings 2022-03-31 01524904 d:Buildings d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 01524904 d:PlantMachinery 2022-04-01 2023-03-31 01524904 d:MotorVehicles 2022-04-01 2023-03-31 01524904 d:FurnitureFittings 2022-04-01 2023-03-31 01524904 d:OtherPropertyPlantEquipment 2022-04-01 2023-03-31 01524904 d:OtherPropertyPlantEquipment 2023-03-31 01524904 d:OtherPropertyPlantEquipment 2022-03-31 01524904 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 01524904 d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 01524904 d:CurrentFinancialInstruments 2023-03-31 01524904 d:CurrentFinancialInstruments 2022-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2022-03-31 01524904 d:ShareCapital 2023-03-31 01524904 d:ShareCapital 2022-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2023-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2022-03-31 01524904 c:FRS102 2022-04-01 2023-03-31 01524904 c:AuditExempt-NoAccountantsReport 2022-04-01 2023-03-31 01524904 c:FullAccounts 2022-04-01 2023-03-31 01524904 c:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 01524904 d:WithinOneYear 2023-03-31 01524904 d:WithinOneYear 2022-03-31 01524904 6 2022-04-01 2023-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2023-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2022-03-31 iso4217:GBP xbrli:pure
Company registration number: 01524904







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2023


CONSOLIDATED MEDICAL INDUSTRIES LIMITED






































img6b8f.png                        

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
COMPANY INFORMATION


Director
Mr A Hodgson 




Company secretary
Mrs C Hodgson



Registered number
01524904



Registered office
5 Rise Road

Ascot

Berkshire

SL5 0BH




Accountants
Menzies LLP
Chartered Accountants

Magna House

18-32 London Road

Staines-Upon-Thames

TW18 4BP





 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 



CONTENTS



Page
Statement of Financial Position
1 - 2
Notes to the Financial Statements
3 - 8


 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904



STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
159,702
153,568

  
159,702
153,568

Current assets
  

Stocks
  
186,088
109,102

Debtors: amounts falling due within one year
 6 
97,348
102,996

Cash at bank and in hand
  
76,293
173,154

  
359,729
385,252

Creditors: amounts falling due within one year
 7 
(201,400)
(252,330)

Net current assets
  
 
 
158,329
 
 
132,922

Total assets less current liabilities
  
318,031
286,490

Provisions for liabilities
  

Deferred tax
 8 
(13,153)
(6,299)

  
 
 
(13,153)
 
 
(6,299)

Net assets
  
304,878
280,191


Capital and reserves
  

Called up share capital 
  
2,000
2,000

Profit and loss account
  
302,878
278,191

  
304,878
280,191


Page 1

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2023

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr A Hodgson
Director

Date: 9 November 2023

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

1.


General information

Consolidated Medical Industries Limited is a private company limited by shares incorporated in England and Wales. The address of the principal place of business and the registered office is given in the company information page within these financial statements.
The company's financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Turnover is derived from the installation, repair, rental and sale of medical and pharmaceutical equipment and is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. 

 
2.3

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on both a reducing balance and straight-line basis.

Depreciation is provided on the following basis:

Land and buildings
-
20% straight-line
Plant and machinery
-
25% reducing balance
Motor vehicles
-
25% reducing balance
Fixtures and fittings
-
25% reducing balance
Other fixed assets
-
33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 3

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.4

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Income and Retained Earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.5

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.6

Operating leases: the company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.7

Provisions for liabilities

Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the company becomes aware of the obligation, and are measured at the best estimate at the reporting date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

Page 4

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


3.


Employees

The average monthly number of employees, including directors, during the year was 9 (2022 - 8).

Page 5

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

4.


Tangible fixed assets





Land and buildings
Plant and machinery etc.
Total

£
£
£



Cost or valuation


At 1 April 2022
10,000
357,892
367,892


Additions
-
66,394
66,394


Disposals
-
(6,999)
(6,999)



At 31 March 2023

10,000
417,287
427,287



Depreciation


At 1 April 2022
10,000
204,324
214,324


Charge for the year on owned assets
-
53,407
53,407


Disposals
-
(146)
(146)



At 31 March 2023

10,000
257,585
267,585



Net book value



At 31 March 2023
-
159,702
159,702



At 31 March 2022
-
153,568
153,568

Page 6

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2022
150,750



At 31 March 2023

150,750



Impairment


At 1 April 2022
150,750



At 31 March 2023

150,750



Net book value



At 31 March 2023
-



At 31 March 2022
-


6.


Debtors

2023
2022
£
£


Trade debtors
91,948
55,553

Other debtors
5,400
8,250

Prepayments and accrued income
-
39,193

97,348
102,996


Page 7

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
23,320
54,647

Corporation tax
3,890
-

Other taxation and social security
12,768
15,612

Other creditors
150,958
173,323

Accruals and deferred income
10,464
8,748

201,400
252,330



8.


Deferred taxation




2023


£






At beginning of year
(6,299)


Charged to profit or loss
(6,854)



At end of year
(13,153)

The provision for deferred taxation is made up as follows:

2023
2022
£
£


Accelerated capital allowances
(13,153)
(6,299)

(13,153)
(6,299)


9.


Commitments under operating leases

At 31 March 2023 the company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2023
2022
£
£


Not later than 1 year
-
16,800

-
16,800

 
Page 8